Phase II proof-of-concept study of ALS 2200 in combination with telaprevir (an interferon-free regimen) in patients with genotype 1 hepatitis C.
Phase of Trial: Phase II
Latest Information Update: 06 Jan 2013
At a glance
- Drugs VX 135 (Primary) ; Telaprevir
- Indications Hepatitis C
- Focus Therapeutic Use
- 06 Jan 2013 Data is expected in the second half of 2013, according to a Vertex Pharmaceuticals media release.
- 01 Nov 2012 Planned initiation date changed from 1 Dec 2012 to 1 Feb 2013, as reported in a Medivir AB media release.
- 28 Sep 2012 New trial record